Vesilute: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 6 sources cited
Overview
Vesilute is a synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson bioregulator family. Its developers list it as a bladder (genitourinary) regulator. The vascular peptide of this family is Vesugen (Lys-Glu-Asp), a different compound. No experimental study of Vesilute in cells, animals or people has been published.
Mechanism of Action
Like other Khavinson bioregulators, Vesilute is proposed to interact with DNA regulatory regions and modulate gene expression in its target tissue, which its developers give as the bladder. No published experiment has tested this for the Glu-Asp dipeptide. The only published data are computer docking results predicting that it binds the amino acid and peptide transporters LAT1, LAT2 and PEPT1, which could carry it into cells. Effects on eNOS, nitric oxide production or adhesion molecules (ICAM-1, VCAM-1) have not been published for Vesilute.
Vesilute Benefits: What the Research Shows
- Khavinson peptide research demonstrates that short peptides (2–4 amino acids) can penetrate cell nuclei and interact with gene regulatory regions
- Studies on vascular bioregulators, such as improved arterial blood flow in 41 men treated with the tripeptide Vesugen, concern a different peptide; no study of Vesilute in people has been published
- Computer docking predicts that the Glu-Asp dipeptide binds the LAT1, LAT2 and PEPT1 transporters; this is the only published data on Vesilute's sequence
Vesilute Dosage
- Standard bioregulator protocol: 1–2 capsules (10–20 mg) daily for 10–30 days
- Injectable (if available): 10 mcg subcutaneously every other day for 10–20 days
- Repeat courses every 3–6 months
- Take on an empty stomach for optimal absorption
- No cycling requirement but periodic breaks between courses are standard practice
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Vesilute Side Effects & Safety
Known Side Effects
- No human or animal studies of Vesilute have been published, so side effects have not been assessed
- Developers describe bioregulator peptides as well tolerated, but Vesilute has no published tolerability data
- Cardiovascular and other adverse events have not been studied
- Theoretical concern about altering gene expression in unintended cell types
Safety Profile
Vesilute has no published safety data of any kind: no human, animal or cell study of the Glu-Asp dipeptide was found, only computer modeling. Its developers describe short peptides as well tolerated, but this has not been tested for Vesilute. The compound is not FDA-approved or regulated as a pharmaceutical in most Western countries. No known contraindications or drug interactions are established. Its efficacy claims have no published evidence, independent or otherwise.
What to Expect
Bioregulator effects are described as subtle and gradual. Week 1–2: No noticeable effects. Week 2 onward: The improvements in circulation, warmth in extremities and vascular function sometimes listed for Vesilute describe the vascular peptide Vesugen, not Vesilute. No published study has measured any effect of Vesilute in people, on the bladder or elsewhere, and repeated courses have not been studied.
Storage & Handling
Store capsules at room temperature (15–25°C), protected from moisture and light. Shelf life: 2–3 years. Injectable form: store lyophilized powder at 2–8°C; reconstituted solution at 2–8°C for up to 14 days.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Khavinson V, Linkova N, Kozhevnikova E, et al. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022.
- Khavinson VK, Linkova NS, Rudskoy AI, et al. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023.
- Fedoreyeva LI, Kireev II, Khavinson VKh, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011.
- Khavinson VK, Popovich IG, Linkova NS, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021.
- Kitachev KV, Sazonov AB, Kozlov KL, et al. The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people. Adv Gerontol. 2014.
- Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012.
Related Peptides
Track Vesilute in Your Protocol
Log your Vesilute doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free